Project Grant R21EY036512
Award Date
9/30/24
Completion Date
6/30/26
Dollars Obligated
$193K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $492,500 project grant awarded by the National Eye Institute (NEI) under CFDA Program 93.867 (Vision Research) aims to develop universally immune-compatible induced pluripotent stem cells (iPSCs) for regenerative ocular therapies. The research project will use CRISPR/Cas9 gene editing to generate iPSCs that express "peptide-free" or "low-affinity" human leukocyte antigen class 1 (HLA-I) molecules, allowing the cells to evade both CD8+ T cell and natural killer...
The National Eye Institute (NEI) awarded a $132,597 Project Grant under the NEI Vision Research program (CFDA 93.867) to The Schepens Eye Research Institute, Inc. The grant supports research aimed at improving retinal ganglion cell (RGC) replacement therapies for glaucoma. The project will investigate the role of neural activity in regulating host RGC integration and remodeling of host-donor visual neural circuits. The research involves developing models to selectively inhibit host RGC...
The National Eye Institute (NEI) awarded a $234,000 Project Grant (CFDA 93.867 - Vision Research) to Oregon Health & Science University (OHSU) for the period of February 1, 2025 to January 31, 2027. The grant supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis in glaucoma through the use of senolytic treatments. The project aims to leverage senotherapeutics to selectively clear senescent trabecular meshwork cells and restore IOP homeostatic...
This $651,846 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to identify the gene regulatory networks controlling temporal patterning in retinal progenitor cells and neurogenic Müller glia. The project aims to determine the specific transcription factors necessary and sufficient to control the progressive changes in retinal progenitor cell competence over developmental neurogenesis. Key objectives include profiling...
The National Eye Institute (NEI) awarded a $592,457 Project Grant (CFDA 93.867 - Vision Research) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, with a project period of September 30, 2024 to August 31, 2029. The funding will support research to characterize the response features of intrinsically photosensitive retinal ganglion cells (ipRGCs), which contain the photoreceptor melanopsin and influence processes such as the circadian clock, sleep, and pupil...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), will fund research to investigate the combined effects of aging and elevated intraocular pressure (IOP) on the development of glaucoma and the retinal ganglion cell (RGC) transcriptome. The $679,159 award, with a project period from May 1, 2025 to April 30, 2029, will be used to (1) demonstrate how AAV2-mediated epigenetic reprogramming with the OSK (OCT4, SOX2, KLF4)...
The National Eye Institute (NEI) awarded a $1,765,704 Project Grant (CFDA 93.867 - Vision Research) to Trustees of Boston University to develop an injectable, high-precision optoacoustic retina prosthesis for minimally invasive stimulation of the retina. The key products and services to be delivered under this 3-year project include: Development of a highly efficient photoacoustic injectable biomaterial for retinal stimulation Demonstration of micrometer-scale (40-50 μm) resolution retinal...
The National Eye Institute (NEI) awarded a $360,897 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotechnology research company, with a period of performance from September 30, 2024 to August 31, 2025. The grant supports the development of a novel combination therapy approach for glaucoma, which involves topical application of an optimized nerve growth factor (NGF) mutein (HC201) and oral supplementation with nicotinamide (NAM). The goal of the Phase 1 study is to...
The National Eye Institute (NEI), under its Vision Research federal grant program (CFDA 93.867), awarded a $247,700 Project Grant (R21EY037023) to the University of Utah to establish a chimeric mouse model for studying human retinal microglia in vivo. The project aims to introduce human induced pluripotent stem cell-derived hematopoietic progenitor cells into newborn mouse brains to generate human xenotransplanted microglia, which will then be characterized in the mouse retina. The study will...
The National Eye Institute (NEI) awarded Tufts Medical Center a 5-year, $421,600 Project Grant (CFDA 93.867 - Vision Research) to investigate the regulatory mechanisms that govern the growth and regression of abnormal blood vessels in the retina, which can lead to vision loss in conditions like retinopathy of prematurity. The project aims to delineate the roles of chemokine signaling in recruiting peripheral immune cells that promote neovascular growth, as well as the function of microglial...